Neuronal exocytosis inhibiting peptides
The invention relates to peptides of general formula (I): R 1 -AA-R 2 (I) which can regulate neuronal exocytosis, their stereoisomers and racemic or non-racemic mixtures thereof, and the cosmetically or pharmaceutically acceptable salts thereof, wherein AA is a sequence of 3 to 40 adjacent amino acids contained in the amino acid sequence of the SNAP-25 protein, R 1 is selected from the group consisting of H or alkyl, aryl, aralkyl or acyl group; and R 2 is selected from the group consisting of amino, hydroxyl or thiol, substituted or non-substituted with aliphatic or cyclic groups, with the condition that when R 1 is H or acetyl, R 2 is not non-substituted amino, hydroxyl or thiol. The invention also relates to a method of obtaining such peptides, cosmetic or pharmaceutical compositions containing them and their use to treat those conditions requiring neuronal exocytosis regulation, preferably for treating the skin.
1. A peptide comprising an amino acid sequence selected from the group consisting of
CH 3 —(CH 2 ) 8 —CO-EEMQRR-NH 2 ,
CH 3 —(CH 2 ) 10 —CO-EEMQRR-NH 2 ,
CH 3 —(CH 2 ) 12 —CO-EEMQRR-NH 2 ,
CH 3 —(CH 2 ) 14 —CO-EEMQRR-NH 2 ,
CH 3 —(CH 2 ) 16 —CO-EEMQRR-NH 2 ,
CH 3 —(CH 2 ) 18 —CO-EEMQRR-NH 2 ,
CH 3 —(CH 2 ) 20 —CO-EEMQRR-NH 2 ,
Ac-EEMQRR-NH—(CH 2 ) 11 —CH 3 ,
Ac-EEMQRR-NH—(CH 2 ) 13 —CH 3 ,
Ac-EEMQRR-NH—(CH 2 ) 15 —CH 3 ,
Ac-EEMQRR-NH—(CH 2 ) 17 —CH 3 ,
Ac-PEG 1 -EEMQRR-NH 2 ,
Ac-PEG 2 -EEMQRR-NH 2 ,
Ac-PEG 3 -EEMQRR-NH 2 ,
Ac-PEG 4 -EEMQRR-NH 2 ,
Ac-PEG 5 -EEMQRR-NH 2 ,
its stereoisomers, mixtures thereof, and its cosmetically and pharmaceutically acceptable salts,
wherein
Ac-PEG n is
and n ranges between 1 and 5.
2. A process of obtaining the peptide of according to claim 1 comprising carrying solid phase peptide synthesis.
3. The process according to claim 2 , wherein it uses protective groups selected from the group consisting of Fmoc/tButyl, Fmoc/trityl and Fmoc/allyl.
4. A cosmetic or pharmaceutical composition comprising a cosmetically or pharmaceutically effective amount of at least one peptide according to claim 1 and at least one cosmetically or pharmaceutically acceptable excipient or adjuvant.
5. The cosmetic or pharmaceutical composition according to claim 4 , wherein the peptide is incorporated in a cosmetically or pharmaceutically acceptable sustained release system or in a carrier selected from the group consisting of liposomes, millicapsules, microcapsules, nanocapsules, sponges, vesicles, micellae, millispheres, microspheres, nanospheres, lipospheres, microemulsions, nanoemulsions, milliparticles, microparticles and nanoparticles.
6. The cosmetic or pharmaceutical composition according to claim 4 , wherein the peptide is adsorbed on a cosmetically or pharmaceutically acceptable organic polymer or solid mineral support selected from the group consisting of talc, bentonite, silica, starch or maltodextrin.
7. The cosmetic or pharmaceutical composition according to claim 4 , wherein the composition has a formulation selected from the group consisting of creams, emulsions of oil and/or silicone in water, emulsions of water in oil and/or silicone, oils milks, balms, foams, lotions, gels, liniments, serums, soaps, unguents, mousses, ointments, bars, pencils and sprays.
8. The cosmetic or pharmaceutical composition according to claim 4 , wherein the peptide is incorporated in solid supports selected from the group consisting of towelettes, hydrogels, adhesive patches, non-adhesive patches and face masks.
9. The cosmetic or pharmaceutical composition according to claim 4 , wherein the peptide is incorporated in make-up line products selected from the group consisting of concealers, make-up foundations, make-up removal lotions, make-up removal milks, eye shadows and lipsticks.
10. The cosmetic or pharmaceutical composition according to claim 4 , wherein the peptide is incorporated in fabrics.
11. A cosmetic or pharmaceutical composition comprising a cosmetically or pharmaceutically effective amount of at least one peptide according to claim 1 , wherein the peptide is at a concentration between 0.00000001% and 20% by weight.
12. A cosmetic or pharmaceutical composition comprising a cosmetically or pharmaceutically effective amount of at least one peptide according to claim 1 , and an additional cosmetically or pharmaceutically effective amount of an active agent selected from the group consisting of an exfoliating agent, a moisturizing agent, a depigmentation or whitening agent, a pro-pigmentation agent, an anti-stretch mark agent, an anti-wrinkle agent, an anti-oxidizing agent, an anti-glycation agent, an NO-synthase inhibitor, an anti-aging agent, an agent that can reduce and/or eliminate under-eye bags, an agent stimulating the synthesis of dermal or epidermal molecules and/or for preventing their degradation, an agent stimulating the proliferation of fibroblasts and/or keratinocytes and for stimulating keratinocyte differentiation, agents intended to improve the dermal-epidermal junction, a skin relaxing agent, a firming agent, an anti-atmospheric pollution and/or anti-free radical agent, an agent acting on capillary circulation and/or microcirculation, a calming agent, an anti-inflammatory agent, an antimicrobial agent, an antifungal agent, an agent acting on cell metabolism, an agent acting on capillary circulation and/or microcirculation, vitamins, a chelating agent, an organic or mineral photoprotection agent that is active against ultraviolet A and/or B rays, and mixtures thereof.
13. A method of regulating neuronal exocytosis regulation in a mammal, comprising administering to a mammal in need a peptide according to claim 1 .
14. A method of treating, cleaning or caring for the skin of a mammal, comprising administering to a mammal in need a peptide according to claim 1 .
15. A method of reducing and/or eliminating facial wrinkles and/or facial asymmetry of a mammal, comprising administering to a mammal in need a peptide according to claim 1 .
16. The method according to claim 15 , wherein the wrinkles are facial expression wrinkles.
17. The method of claim 16 , wherein the administering comprises applying to the forehead, in the space between the eyebrows and/or in the wrinkles and fine lines around the mouth and/or around the eyes.
18. The method of claim 16 , wherein the administering applying by iontophoresis, or by subcutaneous or intradermal injection in the forehead, in the space between the eyebrows and/or in the wrinkles and fine lines around the mouth and/or around the eyes.
19. A method of reducing and/or eliminating muscle spasticity of a mammal, comprising administering to a mammal in need a peptide according to claim 1 .